A pre-clinical healthcare company, Sonnest Inc is structured around development of Electrast™, an ultrasound imaging drug designed to circulate through the body in the inactive state (dark on ultrasound) and that is selectively activated (turned on) in the myocardium: effectively, using ultrasound to transform cardiac care. Employing Electrast™, it is suggested, doctors would have the capacity and capability to evaluate perfusion of the heart quickly and cost-effectively at the point of care without exposure to ionizing radiation or toxic dyes. With financial support from the Coulter-Drexel Program, the technology was originally developed at Drexel University by a talented team of cardiologists and chemical engineers. To form the firm Sonnest, the inventors partnered with a team of serial healthcare entrepreneurs who have successfully worked together for over 15 years across multiple companies.
